This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
New recommendations to boost the competitiveness in UK biopharma and Medtech sectors have been published by Imperial College London. The ‘Sectoral Systems of Innovation and the UK’s Competitiveness’ reports assess the value-added per capita of each sector and how they compare internationally.
The post New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds appeared first on MedCity News. Eli Lilly drug Ebglyss is now FDA-approved for atopic dermatitis, an inflammatory skin disorder also known as eczema. The biologic drug came from Lilly’s $1.1 billion acquisition of Dermira in 2020.
BridgeBio Pharma claims its drug, Attruby, has an edge over a Pfizer drug as a treatment for cardiomyopathy caused by transthyretin-mediated amyloidosis. But new competition to both products could come soon from Alnylam Pharmaceuticals, now set to receive an FDA decision in this indication by late March.
After last year saw the rise of popular obesity treatments, biopharma's interest in the field only appears to only be growing. With Novo Nordisk and Eli Lilly dominating the obesity field, Amgen's CEO Robert Bradway knows a new offering will have to offer a unique benefit.
Authors: | Gain the competitive edge with accurate probability of success assessments to uncover undervalued companies and early-stage assets for acquisitions.
As the innovative, multi-billion dollar industry expands rapidly, pharma companies must consider how to deliver and differentiate. The post The New Radiopharma Competition Requires Unprecedented Medical Logistics appeared first on MedCity News.
The Federal Trade Commission says more than 100 patents from 10 biopharma companies are improperly listed in the FDA’s official publication of approved products. Such listings delay generic competition, which reduces consumer choice and keeps prices high, the regulator said.
The post Eli Lilly Alzheimer’s Drug Lands FDA Approval, Introducing Competition to Eisai’s Leqembi appeared first on MedCity News. In addition to slowing cognitive decline and disease progression, clinical trial results showed that amyloid beta plaques were reduced to the point where some patients could stop taking the infused therapy.
The big three insulin manufacturers have cut prices across their product lineups, but potential competition from other biosimilar insulins is still in earlier stages of development. Insulin prices have long been a pain point for diabetics.
The post Full FDA Approval of Travere’s Kidney Drug Stiffens Competition With Novartis, Calliditas appeared first on MedCity News. The full approval comes nearly a year after the Travere drug narrowly missed the main goal of its confirmatory study.
A new report by the Association of the British Pharmaceutical Industry (ABPI) has identified the UK biopharma industry is increasingly seeking talent with artificial intelligence (AI) and data skills to maintain competitiveness as digital technology continues to drive innovation. This has spiked from 27 in 2019 to 225 in 2022.
However, the Phase 2 results showed only “clinically meaningful” improvement in resolving liver fibrosis, a key measure of the drug’s potential competitiveness in a crowded field of contenders. Eli Lilly reported 74% of patients treated with tirzepatide achieved resolution of metabolic dysfunction-associated steatohepatitis, or MASH.
Back in 2003, drugs from large pharma companies made up 36% of the late-stage R&D pipeline. These data are astonishing, given the perception that Big Pharma is the main driver of biopharma innovation. Yet, we know small-to-mid-sized pharma launches face a unique set of challenges. Not anymore. Download POV
FDA approval of Ascendis Pharma’s Yorvipath is just in time for patients with hypoparathyroidism as Takeda Pharmaceutical will soon stop making the only drug therapy for the rare disorder. But competition could come from others, including an AstraZeneca peptide in late-stage development.
If Ionis can commercialize this drug, competition would include products from Takeda Pharmaceutical and BioCryst Pharmaceuticals. In its Phase 3 test, Ionis Pharmaceuticals drug donidalorsen reduced the frequency of swelling attacks caused by the rare disease hereditary angioedema.
However, China and India are set to be fierce competition over the next decade, with 30 percent of respondents suggesting they would offshore >50 percent of clinical trials and operations to India, China or other lower-cost countries over the next five years.
FDA approval of Sanofi hemophilia A drug Altuviiio provides patients with a therapeutic option that lasts longer than most other products available, including one already marketed by the French pharma giant. Altuviiio also gives Sanofi a way to better compete against blockbuster Roche drug Hemlibra.
MiRecule, winner in the biopharma track of MedCity News’s Pitch Perfect startup competition, is now pursuing a Series A round of financing. RNA therapies developer miRecule is partnered with Sanofi on the development of a treatment for facioscapulohumeral muscular dystrophy, or FSHD.
The move means Sanofi is out of the competitive chase to develop a so-called “oral SERD” therapy for patients with a certain type of breast cancer. Sanofi breast cancer drug amcenestrant has failed in a Phase 3 clinical trial, leading the pharmaceutical giant to discontinue all clinical development of the small molecule.
Cytokinetics drug aficamten met the main goal of a pivotal test in obstructive hypertrophic cardiomyopathy. If approved, the daily pill would compete against a Bristol Myers Squibb drug projected to become a blockbuster seller.
Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA’s decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC). The post Pharma M&A rumour mill grinds out Mirati’s name again appeared first on.
Embarking on the journey from product development to market success in the biopharma industry is no small feat. The landscape is highly competitive with new prescription medications launching worldwide each year. However, this journey is fraught with challenges as revealed by an in-depth analysis.
M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. Since the first wave of consolidation started in 1988, there has been a significant concentration of the pharma industry.
The FDA approved Roche’s Columvi as a third-line treatment for a type of blood cancer called diffuse large B-cell lymphoma. This new Roche drug will compete against Epkinly, AbbVie’s recently approved DLBCL drug.
With pharma/biopharma companies looking to select CDMO partners earlier than before, and in a competitive market, what approaches can be adopted? Included in this Guide to: The changing face of outsourcing. Here, EPR explores some recent trends and evolving strategies. Are you leveraging all the information from your QC data?
While pharmaceutical companies continue to raise list prices year-over-year, we work behind the scenes to fight the trend by driving competition, negotiating with drugmakers and incentivizing the use of less expensive medicines that deliver the same clinical value.
Preliminary weight loss and safety data for Structure Therapeutics’ drug candidate suggest it’s competitive with other oral GLP-1 targeting contenders from big pharma companies.
A drug developed by Protalix BioTherapeutics and Chiesi Group is now FDA approved for treating Fabry disease, a rare inherited metabolic disorder. The drug, Elfabrio, is an enzyme replacement therapy.
Preliminary Phase 2 results show 83% of those treated with Boehringer Ingelheim and Zealand Pharma drug survodutide met the main goal of improvement in the fatty liver disease MASH. Boehringer contends this drug has best-in-class potential in a competitive field that includes an Eli Lilly drug that recently posted positive Phase 2 results.
The restructuring of cardiovascular drugmaker Amarin means the layoff of about 30% of staff. Sales of Vascepa, the company’s only commercialized product, have suffered as generic versions gain traction in the market.
Merck said topline Phase 3 results show an injectable version of Keytruda met the main goal of non-inferiority compared to the intravenously infused formulation that is the pharma giant’s top-selling product. Injectable Keytruda could help Merck compete against coming competition from biosimilars.
Together, these groups compile vast amounts of data, including rich information on patient populations, target customers, and the competitive landscape. Historically, competitive and market analysis data has been stored in spreadsheets. Truly understanding the competitive landscape and market environment.
Amgen’s Lumakras became the first FDA-approved drug that addresses the elusive KRAS mutation, but Mirati believes its newly approved therapy, Krazati, could be better. The small molecule’s features include the ability to penetrate into the brain, where it can address cancer that has spread to the central nervous system.
Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. For biopharma, success in this space will require integrated models that are significantly different than what has been used with historic medicines. In oncology, it’s 47% less.
As the full consequences of the COVID-19 virus started to emerge, and many industries found themselves having to either suspend operations or move to remote working, the biopharma sector found itself on the front line facing unprecedented challenges. R&D ecosystem - Index score 6.54/10.
The FDA approved TheracosBio’s Brenzavvy as a treatment for type 2 diabetes. But before it won a regulatory nod for controlling blood glucose in adults, it was approved at a different dose (with flavor) as a veterinary product.
Pfizer’s Litfulo is the first treatment approved for treating adolescents with severe alopecia areata. The drug’s approval also covers adults, were it will compete against Eli Lilly’s Olumiant.
Numerous clinical, regulatory and financial factors are behind this digital shift in pharma. And in the first quarter of this year, the largest Series A ever in digital health ($203M) went into a company accelerating clinical trials and drug development.
Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. The pace of innovation in biopharma has rocketed over the last two years, with vaccines, new antivirals, and therapies delivered at an unprecedented pace.
Doubling down on strategic therapeutic areas Pharma once again finds itself having to narrow its sights on partnerships that deliver the next blockbuster and enable differentiation from the competition—all while navigating increasing regulatory scrutiny and shifting patient and payer expectations.
Now, as the President of Accord BioPharma , the U.S. PM360: From your time at Roche when you were dealing with biosimilars as potential competition to now leading the launch of biosimilars at Accord and Intas, how have you seen the marketplace for biosimilars evolve over that time? Look, competition is healthy.
With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. This allows for a complementary portfolio fit without the kind of competitive overlap that comes under regulatory scrutiny from the FTC.
Industry observers note that most of these drugs are older products facing generic competition soon, so greater industry impact will come as the program expands to more drugs in years to come. The first 10 drugs selected for Medicare price negotiations now have new prices set to take effect in 2026.
The antibody’s target puts it in competition with drugs from AstraZeneca, Pfizer, and Sanofi. Blackstone Life Sciences startup Uniquity Bio emerged from stealth with an in-licensed drug candidate that could treat a wide range of immunology and inflammation indications.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content